HIGHLIGHTS
ALPK2 is expressed and regulated during hESC cardiomyocyte lineage determination Cardiac development in zebrafish embryos and hESCs requires ALPK2 ALPK2 negatively regulates WNT signaling to promote cardiomyocyte differentiation
INTRODUCTION
Directed differentiation from human embryonic stem cells (hESCs) toward cardiomyocytes serves as an in vitro model to elucidate regulatory mechanisms during human heart development . Differentiation of cardiomyocytes requires temporal regulation of the WNT/ b-catenin signal transduction pathway Lian et al., 2012; Naito et al., 2006; Ueno et al., 2007) . Activation of WNT/b-catenin signaling is essential for the exit from pluripotency and mesoderm formation, whereas repression of the pathway is required for the transition toward the cardiomyocyte lineage (Davidson et al., 2012; . Studies have shown that modulation of the Wnt pathway is sufficient to direct cells through stage-specific transition during differentiation (Burridge et al., 2014; Lian et al., 2012) . Thus, identifying regulators that inhibit WNT/b-catenin signaling is critical toward understanding human heart development.
WNT/b-catenin signaling is regulated by post-translational modifications of b-catenin (Gao et al., 2014; Moon et al., 2004) . A ''destruction complex'' that contains scaffolding proteins and protein kinases phosphorylates b-catenin to display a motif that is recognized for ubiquitylation and degradation by the proteasome (Stamos and Weis, 2013) . Lack of b-catenin phosphorylation activates WNT signaling (Stamos and Weis, 2013) . Stabilized b-catenin shuttles into the nucleus and binds to transcription factors, notably TCF/LEF family members, to activate transcription of WNT target genes (Hsu et al., 1998; MacDonald et al., 2009) . Continued activation of WNT/b-catenin signaling in the mesoderm represses cardiomyocyte fate and promotes endothelial and hematopoietic fate wam\Woll et al., 2008) . Thus, identifying regulators that inhibit WNT/b-catenin signaling is critical to control cell fate decisions during human heart development.
In the current study, by using combinatorial screening we identified a member of an atypical alpha protein kinase family member, alpha protein kinase 2 (ALPK2), as a cardiac developmental regulator and WNT/ b-catenin signaling inhibitor. This protein family shares a highly conserved alpha protein kinase domain and, unlike conventional protein kinases, they are evolutionarily restricted to vertebrates (Middelbeek et al., 2010) . There are six alpha kinases: eukaryotic elongation factor 2 kinase (eEF2K), TRP ion channel proteins (TRPM6 and TRPM7) as well as lymphocyte alpha kinase (LAK, or ALPK1), heart alpha kinase (HAK, or ALPK2), and muscle alpha kinase (MAK, or ALPK3), which were named from the tissues they were derived from (Drennan and Ryazanov, 2004; Middelbeek et al., 2010) . ALPK2 has known roles in cancer by regulating cell cycle and DNA repair genes (Yoshida et al., 2012) and as a candidate regulator of hypertension (C) Chromatin precipitation followed by deep sequencing (ChIP-Seq) for histone marks H3K4me3, H3K36me3, and H27K4me3 in hESC-derived cultures: hESC (day 0), mesoderm (day 2), cardiac progenitor cells (CPCs, day 5), and cardiomyocytes (day 14) (N = 2). (D) Protocol for high-density monolayer-directed differentiation of hESC-derived cardiomyocytes yielding a high percentage of cardiac troponin T (TNNT2)positive cells by flow cytometry. (E) Quantitative RT-PCR analysis of markers of mesoderm (Brachyury T, BRYT), cardiac progenitor cells (T-box 5, TBX5), cardiomyocytes (TNNT2), and ALPK2 at days 0, 2, 5, 14 during cardiomyocyte differentiation. (Chauvet et al., 2011) , whereas its role during heart development has not been characterized. Our data indicate that one function of ALPK2 is to negatively regulate WNT/b-catenin signaling during cardiac development in hESCs and zebrafish.
RESULTS

ALPK2 Is Expressed and Regulated during Cardiomyocyte Development
To identify negative regulators of the WNT/b-catenin signaling pathway, we conducted a combinatorial screen comparing previously published RNA expression from hESC-derived mesoderm and cardiac progenitor cells (CPCs) with a small interfering RNA (siRNA) screen using human colorectal cancer cells (hRKO) carrying a b-catenin-activated reporter (BAR) driving luciferase (James et al., 2009 ) ( Figure 1A ). By intersecting these datasets we identified genes that were highly induced in CPCs that significantly increased BAR activity following siRNA knockdown. This analysis identified a previously unidentified putative cardiac and WNT/b-catenin signaling protein kinase, alpha protein kinase 2 (ALPK2; Figure 1B ). ALPK2 was induced 68-fold in CPCs and increased BAR activity by 4-fold following siRNA-mediated knockdown.
We further explored the role of ALPK2 by surveying the epigenetic landscape over a staged time course of cardiomyocyte differentiation from hESCs . Epigenetic histone modification of chromatin marks H3K4me3 (active promoters) and H3K36me3 (RNA polymerase II activity) show that ALPK2 is epigenetically regulated as cells transition from mesoderm (day 2) to CPCs (day 5) and definitive cardiomyocytes (CMs, day 14) ( Figure 1C ). Of note, the repressive histone mark, H3K27me3, was not altered throughout the differentiation process ( Figure 1C ). We aimed to further characterize the expression of ALPK2 and assess its role during heart development. Toward this goal, hESCs were differentiated into cardiomyocytes using a high-density monolayer differentiation protocol . Differentiation of hESCs was induced with Activin A and bone morphogenetic protein 4 (BMP4) coupled with serial small molecule activation and inhibition of canonical WNT/b-catenin signaling ( Figure 1D ). This directed differentiation protocol typically yields high-purity cardiomyocytes (>80% cardiac troponin T; TNNT2 + ) as assessed by flow cytometry ( Figure 1D ). We analyzed transcript abundance in undifferentiated hESCs (day 0), mesodermal cells (day 2), CPCs (day 5), and cardiomyocytes (day 14). Expression of the pan-mesodermal marker Brachyury T (BRYT) peaked on day 2 and decreased to baseline levels by day 5. Following the peak of BRYT expression, the early cardiac marker T-box 5 (TBX5) could be detected at days 5 and 14. Lastly, the sarcomeric gene cardiac troponin T (TNNT2) was robustly expressed on day 14. These data indicated that normal mesoderm formation, CPC specification, and cardiomyocyte differentiation occurred. Analysis of ALPK2 during this time course showed expression starting at day 5 with increasing levels at day 14 ( Figure 1E , 2896-fold induction from pluripotency), demonstrating that ALPK2 is temporally expressed during specification of CPCs and cardiac commitment.
We subsequently compared the expression and epigenetic regulation of ALPK2 in three distinct mesodermal progenitor cell lineages (CPCs, endocardial-like endothelial cells [ECs] , and hemogenic ECs) to decipher whether ALPK2 was expressed and regulated in non-cardiomyocyte lineages. These populations are generated by specifying distinct mesodermal sub-populations at the onset of differentiation by stimulation with different doses of Activin A and BMP4 as described in the Transparent Methods . We compared RNA sequencing and H3K4me3 and H3K27me3 histone modification at the ALPK2 locus and observed that ALPK2 was highly expressed and regulated in CPCs but not in endocardial-like ECs or hemogenic ECs ( Figure 1F ) . In total, these data indicate ALPK2 is specifically regulated as hESCs differentiate toward the cardiomyocyte lineage.
Zebrafish (Danio rerio) are used as an in vivo model of heart development owing to the highly conserved developmental mechanisms and genome similarities to humans (Bakkers, 2011; Howe et al., 2013; Stainier and Fishman, 1994) . In particular, sequence analyses show that among vertebrates, ALPK2 exhibits a high Figure 1 . Continued (F) RNA sequencing and ChIP-seq for H3K4me3 and H27K4me3 at the ALPK2 locus in CPCs, endocardial-like endothelial cells (EC), and hemogenic ECs (N = 2). (G) In situ hybridization of zebrafish alpk2 and gata4 at 13 hpf and 22 hr post fertilization (hpf, N = 22-36) . Green arrowheads denote adaxial cells and primitive somites, black arrowheads mark the bilateral heart fields, and yellow arrowheads denote the primitive heart. Sample size N = 3-5 biological replicates, and data are displayed as mean G SEM unless otherwise noted. See also Figure S1 . degree of conservation particularly within the alpha kinase domain ( Figure S1 ). To visualize spatiotemporal expression during whole embryo development we analyzed zebrafish alpk2 by in situ hybridization and compared its expression profile to a cardiac transcription factor, gata4. At 13 hr post fertilization (hpf), gata4 is expressed in the bilateral heart, forming fields of pre-cardiac mesoderm, whereas alpk2 is expressed in the precursor cells of slow twitch muscle fibers (adaxial cells) of the paraxial mesoderm. At 22 hpf, gata4 and alpk2 are co-expressed in the developing heart ( Figure 1G ). Thus ALPK2 is expressed during cardiac development in vivo and in vitro.
Depletion of Alpk2 Impairs Zebrafish Heart Development
We next sought to determine the role of ALPK2 in vivo by depleting Alpk2 in zebrafish using splice-blocking morpholino oligonucleotides (MO). Injection of Alpk2 MOs caused alternative splicing and exon 4 removal to create a premature stop codon in exon 6 (Figures 2A-2D ). Alpk2 morphants showed no observable structural defects at 24 hpf when compared with animals injected with scrambled negative control MOs (Figures 2E and 2F). However, transcriptional profiling of a panel of genes with known roles in early heart development (nkx2.5, gata4, mef2ca, mef2cb, cmlc2, tnnt2, atp2a2, cacnalc2, cx43, and ryr2) revealed that Alpk2 morphants had significantly reduced mRNA expression in all transcripts except nkx2.5 and ryr2 at 24 hpf ( Figure 2G ). At 48 hpf, Alpk2 morphants showed a significantly reduced heart beating rate (control 120.0 G 1.29 bpm; alpk2 MO2 60.0 G 2.19 bpm; Figure 2H ) and cardiomyocyte numbers (cmlc2:DsRednuc; control 259 G 21, Alpk2 MO 119 G 8; 51 hpf; Figures 2I-2K). Of note, no difference in staining of endothelial cells was observed on the basis of activated leukocyte cell adhesion molecule (ALCAM; Figures  2I-2K ). By 72 hpf, Alpk2 morphants displayed pericardial and yolk sac effusion and pronounced cardiac malformation coupled with defects in posterior development ( Figures 2L-2O ). We also assessed epicardium formation in fish lacking Alpk2 using zebrafish carrying a florescence epicardial cell reporter (tcf21:DsRed . The zebrafish epicardium is the serosal epithelial lining of the heart derived from an extra-cardiac source of cells termed the proepicardium that is located adjacent to the pericardial sac and the venus pole during primitive heart tube formation (Plavicki et al., 2014; Serluca, 2008) and requires normal cardiac fitness to form (Peralta et al., 2013; Plavicki et al., 2014) . In contrast to controls, Alpk2 morphants lacked tcf21 + ventricular epicardium at 96 hpf. During normal development, this is a time when the epicardium envelops the zebrafish heart ventricle but not the atrium ( Figures 2P and 2Q ; white arrowheads) (Plavicki et al., 2014) .
There remains controversy regarding the use of MOs to study gene function (Rossi et al., 2015; Schulte-Merker and Stainier, 2014) . To address this, we used CRISPR/Cas9 mutagenesis to induce indel mutations in exon 2 of Alpk2. Pilot studies indicated that the F0 fish had significant cardiac defects and posterior developmental anomalies that phenocopied the MO experiments. To avoid possible artifacts associated with mosaic mutations in the injected embryos, we derived an F1 line of fish with a heterozygous 5-base pair frameshift mutation within exon 2 of Alpk2 that resulted in a premature stop codon at amino acid 159 (Alpk2D5, Figures 3A-3D ). Heterozygous fish showed no obvious developmental phenotype and were crossed to generate F2 homozygous Alpk2D5 fish. As with the Alpk2 morphants, there was no overt phenotype observed at 24 hpf in homozygous Alpk2D5 mutants. However, following heart tube formation, Alpk2D5 homozygotes display pericardial and yolk sac effusion, pronounced cardiac malformation coupled with reduced heart beating rate ( Figures 3E-3I ). Of note, cardiomyocyte numbers were not assessed in Alpk2D5 fish. Hemoglobin-peroxidase staining with o-Dianisidine shows that Alpk2D5 fish form erythrocytes but they lack blood circulation in the caudal trunk ( Figures 3J-3K 0 ). This suggests circulation defects that are secondary to reduced heart function. These results indicate that Alpk2 plays an important role in determining the number of cardiomyocytes, normal cardiac morphology, epicardium formation, and cardiac function.
ALPK2 Promotes Differentiation of hESC-derived Cardiomyocytes
To determine whether ALPK2 plays a functional role in human cardiomyocyte development, ALPK2 was knocked down (KD) by lentiviral short hairpin RNAs (shRNA) in hESCs ( Figures 4A and 4B) , and cells were subjected to cardiomyocyte differentiation. ALPK2 KD significantly diminished ALPK2 expression throughout the differentiation process ( Figure 4C ) without disrupting hESC colony morphology or pluripotency-associated gene expression ( Figure 4D ). To assess the role of ALPK2 during early developmental stages, transcript abundance of markers of mesoderm, CPCs, and definitive cardiomyocytes were assessed on days 2, 5, and 14 of differentiation ( Figure 1D ). Although there was no change in the expression of the pan-mesoderm marker, BRYT, expression of CPC markers, TBX5 and Islet 1 (ISL1), and TNNT2 was downregulated in ALPK2 KD cells ( Figures 4E-4H ). In addition, ALPK2 KD cells preferentially differentiated toward a TNNT2-negative and smooth muscle actin (SMA)-positive cell type ( Figures 4I-4L ). These data suggest ALPK2 plays a role during transitioning from mesoderm toward the cardiomyocyte lineage. To further test this hypothesis, we assessed the differentiation efficiency of ALPK2 KD in forming endocardial-like EC and hemogenic EC from mesodermal sub-populations. These results showed no effect on the percentage of endocardial-like or hemogenic ECs (based on KDR/CD34 expression on day 5 of differentiation, Figure S2 ), indicating ALPK2 specifically plays a role in potentiating the cardiomyocyte lineage.
We characterized potential downstream effectors of ALPK2 by performing label-free quantitative (LFQ) proteomics in hESCs undergoing cardiac-directed differentiation ( Figure S3A , Table S2 : All proteins identified by LFQ proteomics. Related to Figure 4 ). To assess the effect on early cardiac cell fate specification, hESCs were transduced with either control or ALPK2 shRNAs and analyzed as hESCs or after differentiation as CPCs. Normalized protein digests were measured by nano-liquid chromatography-tandem mass spectrometry (LC-MS/MS) on a Fusion Orbitrap mass spectrometer and quantified using label-free methods . Label-free quantification was reproducible across all samples, with an average Pearson's correlation of 0.90 ( Figure S3B ; representative image). To validate our approach, we analyzed TNNT2 and ALPK2 protein expression over hESC cardiomyocyte differentiation. As expected, both TNNT2 and ALPK2 protein levels increased as cells differentiated toward cardiomyocytes ( Figures S3C and S3D ). ALPK2 protein expression increased progressively as control hESCs differentiated into CPCs and then into cardiomyocytes, paralleling the mRNA expression pattern. Following treatment with ALPK2 shRNA lentiviruses, ALPK2 protein was decreased in CPCs and cardiomyocytes ( Figure S3D ).
Next, we performed unbiased hierarchal cluster analysis of samples and found replicates and experimental conditions cluster together ( Figure S3E ). We analyzed ALPK2-regulated proteins by using p % 0.05 and a cutoff of 2-fold (log2) change. This analysis identified 241 ALPK2-regulated proteins in CPCs (126 upregulated, 115 downregulated; Figure 4M , Table S3 : ALPK2-regulated proteins identified by LFQ proteomics in cardiac progenitor cells. Related to Figure 4 ). We observed no ALPK2-regulated proteins between control and ALPK2 KD undifferentiated hESCs. Gene ontology (GO) term analysis revealed that ALPK2 regulates processes involved in RNA and protein binding, protein kinase binding, cell-cell adhesion, the extracellular matrix, and actin filaments and function, and canonical WNT signaling (Tables S4: GO Terms enriched Table S5 : GO Terms repressed by ALPK2 knockdown identified by LFQ proteomics in cardiac progenitor cells. Related to Figure 4 ). Specifically, ALPK2 KD reduced TNNT2 and GATA4 expression in CPCs ( Figure 4N ) and induced the expression of the WNT/b-catenin antagonist and secreted frizzled-related protein (sFRP1) (Ren et al., 2013) as well as the WNT signaling transducer b-catenin (CTNNB1) ( Figure 4N ). These proteomic data suggest ALPK2 regulates key mediators of the WNT/b-catenin signaling pathway and cardiac developmental proteins during cardiomyocyte differentiation.
ALPK2 Negatively Regulates WNT/b-Catenin for Cardiac Development
The LFQ proteomics indicate that ALPK2 knockdown affects WNT/b-catenin signaling during cardiac development. To more definitively assess the role of ALPK2 in regulating WNT/b-catenin signaling, we stably transduced a lentiviral BAR driving venus expression in hESCs ( Figure S4A ). BAR-hESCs were subsequently transduced with control or ALPK2 shRNAs and were subjected to directed differentiation toward CPCs, followed by assessment of venus expression analysis by live-cell flow cytometry ( Figure S4B ). ALPK2 KD significantly reduced ALPK2 expression ( Figure 5A ) and increased the overall mean live-cell venus fluorescence intensity (geometric mean: control, 2.39 G 0.03 x 10 3 ; ALPK2 KD, 3.01 G 0.44 x 10 3 ) and significantly increased the percentage of venus-expressing CPCs (venus + /DsRed + ; control %, 18.4 G 0.8; ALPK2 KD %, 27.6 G 0.4) ( Figure 5B ), indicating ALPK2 KD increases b-catenin-dependent WNT signaling.
To further assess the role of ALPK2 and WNT/b-catenin signaling we used CRISPR/Cas9 gene editing to mutate the protein kinase domain of ALPK2 in hESCs. This approach successfully created an hESC line carrying a homozygous 10-bp frameshift deletion causing a premature stop codon in exon 9 (ALPK2D10; Figures S4C and S4D ). Wild-type and ALPK2D10 hESCs were differentiated to CPCs ( Figure 1D) , and transcript abundance of ALPK2 was measured by RT-qPCR. ALPK2D10 CPCs had a significantly reduced ALPK2 expression when compared with control ( Figure S4E ), suggesting ALPK2D10 cells undergo nonsensemediated mRNA decay. ALPK2D10 and wild-type hESCs were subsequently differentiated toward cardiomyocytes as described in Figure 1D and analyzed by immunoblotting and TNNT2 flow cytometry on days 5 and 14, respectively. We characterized the expression of LRP6, pLRP6, CTNNB1, and LEF1 as indicators of active WNT/b-catenin signaling in CPCs lacking ALPK2. The WNT co-receptor, LRP6, is phosphorylated by glycogen synthase kinase 3 beta (GSK3b) and casein kinase 1 (CK1) upon WNT ligand binding (Davidson et al., 2005; Zeng et al., 2005) . Furthermore, induction of WNT/b-catenin signaling is associated with induced expression of target proteins such as LEF1 (Hsu et al., 1998) . The expression of pLRP6, CTNNB1, and LEF1 proteins was increased in ALPK2D10 CPCs when compared with wild-type CPCs ( Figure 5C ). To further examine the role of ALPK2 during WNT/b-catenin signaling we analyzed the expression of LEF1 using wild-type and ALPK2D10 CPCs with or without a small molecule WNT/b-catenin signaling inhibitor, XAV939 (0 or 1 mM). In wild-type cells, XAV939 reduced LEF1 expression to almost undetectable levels.
Although baseline LEF1 levels are increased in ALPK2D10 CPCs, treatment with XAV939 also reduced LEF1 protein abundance ( Figure 5D ), suggesting that at least part of the ALPK2's Wnt-suppression effect occurs upstream of the Axin-stabilizing enzyme, tankyrase, the target for XAV939 (Huang et al., 2009 ).
Next, we sought to rescue the ALPK2-mediated cardiomyocyte differentiation defects by attenuating WNT/b-catenin signaling with increasing doses of the pathway inhibitor, XAV939. Wild-type and ALPK2D10 cells were exposed to 0, 1, and 5 mM XAV939 on day 3 of the differentiation protocol for 2 days, and cells were collected on day 14 for flow cytometry analysis (TNNT2). XAV939 showed a dose-dependent ability to restore the cardiogenic potential of ALPK2D10 cells, such that exposure to 5 mM XAV939 restored cardiac differentiation to wild-type levels ( Figure 5E ). Thus inhibition of WNT/b-catenin signaling can restore cardiomyocyte differentiation deficiencies observed in ALPK2D10 cells.
WNT/b-catenin signaling pathway modulation is required for the differentiation of the epicardium in hESCs (Bao et al., 2016; Iyer et al., 2015) , and Alpk2-depleted zebrafish showed impaired formation of the epicardium ( Figure 2 ). To test more specifically for a role of WNT/b-catenin signaling in epicardium formation in zebrafish, we genetically overexpressed wnt8 to induce canonical WNT signaling using a heat-shock-inducible zebrafish line (hsp70:wnt8b-GFP ) crossed to an epicardial cell reporter (tcf21:DsRed). Fish were subjected to heat shock following heart tube formation (24 and 48 hpf), and epicardial formation was assessed at 96 hpf. As with zebrafish depleted of Alpk2, late embryo-larval activation of WNT/b-catenin signaling inhibited the formation of the epicardium ( Figure 5F ). Collectively, these data demonstrate that inhibition of WNT/b-catenin signaling by ALPK2 is required for the formation of both the myocardium and epicardium.
Quantitative Phosphoproteomics Reveals Phosphorylation Motif and Candidate Substrate Proteins for ALPK2
To identify ALPK2 targets we conducted quantitative phosphoproteomics comparing wild-type with ALPK2D10 CPCs (see Transparent Methods in Supplemental Information and Figure 6A ). Wild-type and ALPK2D10 CPCs were collected and processed for proteomics and phosphoproteomics following stable isotope labeling with amino acids in cell culture (SILAC) and directed differentiation. We detected 2,664 proteins, of which 317 (157 induced, 160 repressed) were differentially expressed (R2-fold; log2; Figures  6B and S5 , and Table S6 : All proteins identified by SILAC proteomics. Related to Figure 6 ). GO term analysis revealed that ALPK2-regulated proteins have known roles in negative regulation of WNT/b-catenin signaling and b-catenin-TCF complex assembly along with proteins that play roles in regulating heart development and actin behavior and function ( Figure S6C , Table S7 : GO Terms enriched in ALPK2D10 cardiac progenitor cells identified by SILAC proteomics. Related to Figures 6 and S8: GO Terms repressed in ALPK2D10 cardiac progenitor cells identified by SILAC proteomics. Related to Figure 6 ).
We validated the proteomics screen by immunoblotting for two proteins with known roles in modulating canonical and non-canonical WNT signaling. Protein kinase N2 (PKN2) has previously been described as a negative regulator of WNT/b-catenin signaling (James et al., 2013) and was predicted to be upregulated in CPCs derived from ALPK2D10 hESCs. Alternatively, the cell polarity and non-canonical WNT signaling regulator, Scribble (SCRIB) (Sisson et al., 2015) , was predicted to be unchanged in ALPK2D10 CPCs. Western blotting for PKN2 and SCRIB confirmed that in ALPK2D10 CPCs, PKN2 was upregulated and SCRIB was not changed ( Figure 6B ).
We also detected and quantified 1,972 phosphopeptides corresponding to 846 proteins ( Figure 6C , Table S9 : All phosphopeptides identified and differentially phosphorylated in ALPK2D10 cardiac progenitor cells identified by SILAC proteomics. Related to Figure 6 ). Phosphorylation motif analysis revealed that PDS5B  FAM122A  TNKS1BP1  PCM1  TNIK  NUFIP2  JPH2  IRF2BP1  SCRIB  PALM  MARCKS  SVIL  ANKRD17  TERF2  AAK1  ARID1A  FOXK2  REST  STIM1  PTTG2  HIST1H1B  KIAA1462  BAG3  PAGR1  SLC9A3R1 ALPK2 is predicted to target proteins carrying serine-proline amino acid residues ( Figure 6D ). Of the predicted ALPK2 target substrates (proteins that lack phosphorylation in ALPK2D10 CPCs), approximately one-third have known roles in regulating WNT/b-catenin signaling (32.6%) and heart development and disease (34.7%, Figure 6E ). Thus our data support the hypothesis that ALPK2 regulates cardiac development by phosphorylating substrates that are associated with WNT/b-catenin signaling during heart development.
DISCUSSION
Regulation of WNT/b-catenin signaling has long been known to be essential for heart development, homeostasis, and disease Moon et al., 2004 Moon et al., , 2017 Ozhan and Weidinger, 2015; Ueno et al., 2007) . We used targeted combinatorial screening from cardiomyocyte differentiation of hESCs coupled with siRNA screen of human cancer cells to identify previously unknown regulators of heart development and WNT/b-catenin signaling. In this study, we demonstrate that knockdown and knockout of ALPK2 in vivo and in vitro result in diminished cardiogenesis and increased WNT/b-catenin signaling activity. ALPK2 is highly expressed in a stage-dependent manner during cardiogenesis and is an important regulator of cardiomyocyte differentiation in hESCs and cardiac development in zebrafish. Furthermore, we find that ALPK2 regulates cardiogenesis by repressing WNT/b-catenin signaling following cardiac commitment. We sought to understand how ALPK2 regulates WNT/b-catenin signaling during cardiogenesis by performing quantitative proteomic screens. These screens further supported our combinatorial efforts by identifying that ALPK2 regulates cardiac proteins along with mediators of the WNT/b-catenin signaling pathway. We consistently observe an increased expression of proteins that inhibit WNT/b-catenin signaling following depletion of ALPK2. Key examples of this are the canonical WNT proteins, PKN2, and sFRP1 that could very likely be induced as a compensatory mechanism to repress the pathway.
Comparing multiple model systems to understand gene function is critical owing to gene duplication, species variation, or compensatory mechanisms (Jensen et al., 2013; Olson, 2006; Rossi et al., 2015) . Expression analyses of alpk2 in zebrafish embryos demonstrate that it is expressed in the developing heart, whereas in human ESCs, ALPK2 is expressed in the cardiac progenitor cells and cardiomyocytes. Correspondingly, both model systems show significant defects in cardiogenesis when ALPK2 is knocked down or knocked out.
Taken together, the vertebrate heart requires precise control of signaling cascades to orchestrate dynamic cell fate decisions and morphogenetic changes during development. We identified that the regulation of the WNT/b-catenin signaling pathway by ALPK2 plays a critical role in hESC-CM differentiation and in cardiac maturation in zebrafish. Thus we report ALPK2 is an evolutionarily conserved alpha protein kinase that is important for the earliest stages of vertebrate heart development through repression of WNT/b-catenin signaling.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file. 
SUPPLEMENTAL INFORMATION
Transparent Methods
Cell culture and cardiac directed differentiation.
Human embryonic stem cells (RUES2) were maintained and cardiac directed differentiation was performed based on methods previously described . Briefly, hESCs were seeded on Matrigel (BD) coated plates and directed differentiation was performed using a combination of activin A and BMP4 and small molecule activation and inhibition of the WNT/β-catenin signaling pathway as illustrated in Figure 1D . Endothelial differentiation was performed as previously described . Briefly, differentiation was initiated with Activin A (100 ng/mL for endocardial-like endothelium (EECs) and 50 ng/mL for hemogenic endothelium (HECs)) in RPMI B27 without insulin and 1x matrigel. On day 1, media was changed to BMP4 (5 ng/mL for EECs and 40 ng/mL for HECs) in RPMI B27 minus insulin with 1 µM CHIR- 
Zebrafish strains and husbandry.
Wild-type (AB; zebrafish International Resource Center, Eugene, OR, USA), tcf21:DsRed2 , cmlc2:DsRed-nuc (Mably et al., 2003) , myl7:GFP (Burns et al., 2005) and hsWNT8:GFP were used and maintained using standard procedures (Westerfield, 2000) in accordance with the Institutional Animal Care and Use Committee-approved protocols.
Flow Cytometry.
Cardiomyocyte purity and immaturity was assessed by flow cytometry using cardiac troponin T (Thermo Scientific, 1:100) antibody and smooth muscle actin (SMA; Abcam, Table S1 . Figure 1C is based on the following data set: NCBI Gene Expression Omnibus (GEO;
Analysis of RNA-seq and chromatin dynamics.
GSE35583, epigenetics; GSE19090, gene expression; previously deposited . Figure 1F is based on the following data set: GEO: GSE97080 .
In situ hybridization.
Wild type zebrafish embryos were collected at 13 and 22 hpf, fixed in 4% paraformaldehyde, dehydrated to methanol, and stored at -20°C until needed. A 613 base pair fragment spanning of alpk2 was amplified from embryonic zebrafish cDNA using primers listed in Table S1 and the digoxigenin-UTP (Roche) antisense alpk2 riboprobe was synthesized using T7 RNA polymerase (Promega). The gata4 riboprobe was previously synthesized and in situ hybridization was performed as previously described . Images were obtained using a Nikon SMZ1500 microscope using a Nikon Digital DS-Ri1 camera.
Morpholino Oligonucleotides.
Translation and splice blocking morpholino oligonucleotides (MO) (GeneTools LLC, Philomath, OR) were injected into one-cell zebrafish embryos (0.25-1 ng/embryo).
Validation of splicing was confirmed by reverse transcriptase PCR following first strand cDNA synthesis (Invitrogen) using primers designed to amplify the flanking region of intron-exon 4 (f1, r1; exons 4-6) as well as downstream the splice junction (f2, r2; exons 5-6). Primers and MO sequences can be found in Table S1 and validation is illustrated in Figure 2A -D.
CRISPR/Cas9 gene editing
Human and zebrafish guide sequences were designed using CRISPRscan software (Moreno-Mateos et al., 2015) and are listed in Table S1 . Human sgRNA oligonucleotides were designed with overhangs for ligation into a BbsI (ThermoFisher Scientific) digested pSpCas9(BB)-2A-Puro (px459) V2.0 (gifted from Feng Zhang, Addgene plasmid # 62988) single vector expression system (Ran et al., 2013) . Human
PSCs were transfected with 1 μg of the ALPK2 sgRNA-PX459 plasmid using GeneJuice (EMD Millipore and hESCs with plasmid integration were selected using puromycin (InvivoGen). Confirmation of mutation and stop codon was conducted by Sanger sequencing. Zebrafish sgRNA and nCas9 was synthesized, injected, and screed as previously described . Founder fish (F0) were outcrossed to with wild type AB fish to generate a stable Alpk2 hemizygous line (F1). F1 fish were subsequently propagated and hemizygous fish were bred to attain homozygosity.
Validation of mutations were conducted through Sanger sequencing. Guide sequences and primers used for validation are listed in Table S1 .
Immunohistochemistry and confocal microscopy.
Zebrafish antibody staining was performed as previously described shRNAs. All ALPK2 shRNAs resulted in significant reduction (72-83%) of ALPK2 when compared to the empty vector shRNA controls ( Figure 4B ). For assessing WNT/βcatenin activity, hESCs were transduced with a lentiviral β-catenin-activated reporter (BAR) driving venus as previously reported .
Cells were lysed in ice-cold cell lysis buffer (Cell Signaling, cat# 9803) containing protease inhibitors (Calbiochem, cat# 539134) and quantification of total protein was conducted using the Pierce BCA Protein Assay Kit (Thermo Scientific). Normalized total protein was subjected to SDS-PAGE and western blotting was performed as previously described (Yang et al., 2014) . Primary antibodies used are listed below were coupled with either anti-mouse, anti-goat or anti rabbit horseradish peroxidase secondary antibody at 1:5000 (Santa Cruz Biotechnology). reverse human sequences as well as common contaminants. We analyzed two biological replicates per condition with six technical replicates. Peptides were searched using a 5ppm mass error and a match between run window of 2min. Gene ontology term analysis was conducted using DAVID functional analysis.
Manufacturer
Statistics. Single variable analysis between two samples was carried out using
Student's t-test. Single and multivariable assays were analyzed by one-or two-way ANOVA. Results are presented as mean±SEM. For all statistically significant results, *P<0.05. 
